Business
Akari is developing next-generation antibody-drug conjugates built around proprietary payloads, with AKTX-101 targeting Trop-2 as the lead candidate.
Akari remains a pre-revenue oncology ADC company, with FY2025 cash burn improving to $10.6M.
The read at a glance✓ Audited against SEC data
- Business mix — Pre-revenue oncology ADC platformWatch
- Revenue — No FY2025 revenue in local rowsWatch
- Cash — Free cash flow improved to -$10.6MNote
- Profitability — Net loss narrowed to $17.3MNote
- Balance sheet — Equity improved to $28.3MOK
- Insiders — 3 buys / 0 sellsOK
- Accounting — No forensic screen in bundleNote
Leadership changes
From Akari Therapeutics Plc's own filings, the day they're filed.
- Samir R. Patel · Chief Executive Officer · departureeff. 2025-04-14
- Michael Grissinger · Director · departureeff. 2024-12-16
- Wendy DiCicco · Chief Financial Officer · departureeff. 2024-12-06
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-07-02
- 8-K · Company announcement2026-06-26
- DEF 14A · Annual proxy (pay & governance)2026-06-04
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Akari Therapeutics Plc, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.